Aprea Therapeutics, Inc. Common stock

APRE

...

APRE: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Show APRE Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of APRE by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by APRE's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

No new patents for this ticker

U.S. Patents Dashboard

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on APRE's company Twitter account

WallStreetBets

Number of mentions of APRE in WallStreetBets Daily Discussion

APRE News

Recent insights relating to APRE

CNBC Recommendations

Recent picks made for APRE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in APRE

Corporate Flights

Flights by private jets registered to APRE